预约演示
更新于：2025-05-15
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2025-05-15
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [17] |
作用方式 拮抗剂、抑制剂 |
作用机制 5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
438
项与 草酸艾司西酞普兰 相关的临床试验NCT06937476
Investigation of the Neurobiological Mechanisms Underlying Pathological Rumination and the Pharmacological Effects of Aripiprazole
NCT06826326
A 'Proof of Concept' Study to Identify Neural Target Engagement of Escitalopram in Adolescents With Autism Spectrum Disorder
NCT05603104
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
3,570
项与 草酸艾司西酞普兰 相关的文献（医药）2025-05-01WATER RESEARCH
Fate and transformation of psychotropic drugs in urban wastewater systems and receiving rivers via the integration of targeted and suspect screening analysis
Article
作者: Hu, Li-Xin ; Xu, Mei-Ying ; Yu, Zhi-Qiang ; Liang, Yin-Xiu ; Liu, You-Sheng ; Ying, Guang-Guo ; Zhang, Jin-Na ; Wang, An-Guo
Psychotropic drugs rank among the most prescribed pharmaceuticals in the world. The ubiquitous occurrence of psychotropic drugs in the environment evoked rising concerns due to their various toxic effect on non-target organisms at low concentrations. However, the removal, transformation, and discharging of these drugs throughout wastewater treatment plants (WWTPs) have rarely been reported. Based on the targeted analysis and suspected screening, this study investigated the distribution of psychotropic drugs and their transformation products (TPs) within the entire treatment processes in WWTPs and their receiving rivers. The results indicated that 13 out of 47 psychotropic drugs are widely observed across wastewater, sludge, receiving river water, and sediment, respectively. The aqueous removal efficiencies of most psychotropic drugs exhibited their significant recalcitrance in wastewater treatment processes. For instance, venlafaxine (VEL) was slightly removed by 2.64 % and 10.8 % in these two WWTPs. The concentrations of oxazepam (OZP) and lamotrigine (LMT) dramatically increased after the overall treatment processes due to their metabolic conversion and regeneration processes, respectively. Given the recalcitrance of psychotropic drugs, the identified TPs generated within WWTPs were not abundant, but a wider variety of TPs were identified from human metabolites. A total of 25 TPs were identified via the suspect screening analysis, of which nine were newly identified. In receiving rivers, the risk quotient (RQ) presented OZP, sertraline (SER), and VEL posed high potential risks; the integration of the toxicological priority index (ToxPi) and the toxicity-weighted concentration (TWC) suggested TP-CIT-322 and TP-OCX-195 as the high-priority contaminants. Given the recalcitrance and environmental risks of psychotropic drugs and their TPs in WWTPs and environments, it is crucial for the further exploration of their effective treatment technologies and emission control strategies .
2025-05-01WATER RESEARCH
Utilizing national wastewater and sales data to derive and validate the correction factors of five common antidepressants for wastewater-based epidemiology
Article
作者: Zhao, Zeyang ; Covaci, Adrian ; Zheng, Qiuda ; Thai, Phong K ; Chen, Shuo ; Mueller, Jochen ; Yuan, Jingyi ; O'Brien, Jake W ; van Nuijs, Alexander L N ; Boogaerts, Tim ; Tscharke, Benjamin J ; Wang, Zhe
Monitoring antidepressant use is important for understanding mental health treatment status in populations and detecting potential misuse. Wastewater-based epidemiology (WBE) is a cost-effective approach to conduct such monitoring but requires valid correction factors (CFs) to accurately convert wastewater mass loads into consumption estimates. Most existing CFs are calculated from pharmacokinetic studies with small cohorts and are not specifically validated for WBE purposes. This study aimed to fill this knowledge gap by calibrating and validating the CFs for 5 commonly prescribed antidepressants. CFs were calibrated by dividing corresponding geo-located sales data by wastewater mass loads from 18 wastewater treatment plants in Australia for the same 3.5-year period. The refined CFs were 9.0 for fluoxetine, 6.4 for venlafaxine, and 25 for quetiapine. For the case of racemic citalopram and the pure S-enantiomer (escitalopram), individual CFs were proposed as 2.0 and 11, respectively. To validate their applicability, the new CFs were applied to independent datasets of wastewater samples collected in Belgium (2019 to 2022) and Australia (2020) and compared with sales data. The new calibrated CFs produced more accurate wastewater-based estimates of consumption for citalopram, escitalopram, fluoxetine, venlafaxine, and quetiapine, enhancing the capability of WBE in public health surveillance.
2025-03-11PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy
Article
作者: Travers, Joshua G. ; Saucerman, Jeffrey J. ; Eggertsen, Taylor G. ; Wolf, Matthew J. ; Hardy, Elizabeth J. ; McKinsey, Timothy A.
Cardiomyocyte hypertrophy is a key clinical predictor of heart failure. High-throughput and AI-driven screens have the potential to identify drugs and downstream pathways that modulate cardiomyocyte hypertrophy. Here, we developed LogiRx, a logic-based mechanistic machine learning method that predicts drug-induced pathways. We applied LogiRx to discover how drugs discovered in a previous compound screen attenuate cardiomyocyte hypertrophy. We experimentally validated LogiRx predictions in neonatal cardiomyocytes, adult mice, and two patient databases. Using LogiRx, we predicted antihypertrophic pathways for seven drugs currently used to treat noncardiac disease. We experimentally validated that escitalopram (Lexapro) and mifepristone inhibit hypertrophy of cultured cardiomyocytes in two contexts. The LogiRx model predicted that escitalopram prevents hypertrophy through an “off-target” serotonin receptor/PI3Kγ pathway, mechanistically validated using additional investigational drugs. Further, escitalopram reduced cardiomyocyte hypertrophy in a mouse model of hypertrophy and fibrosis. Finally, mining of both FDA and University of Virginia databases showed that patients with depression on escitalopram have a lower incidence of cardiac hypertrophy than those prescribed other serotonin reuptake inhibitors that do not target the serotonin receptor. Mechanistic machine learning by LogiRx discovers drug pathways that perturb cell states, which may enable repurposing of escitalopram and other drugs to limit cardiac remodeling through off-target pathways.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 奥地利 | 2002-05-07 | |
| 焦虑症 | 比利时 | 2002-05-07 | |
| 焦虑症 | 塞浦路斯 | 2002-05-07 | |
| 焦虑症 | 丹麦 | 2002-05-07 | |
| 焦虑症 | 芬兰 | 2002-05-07 | |
| 焦虑症 | 法国 | 2002-05-07 | |
| 焦虑症 | 希腊 | 2002-05-07 | |
| 焦虑症 | 冰岛 | 2002-05-07 | |
| 焦虑症 | 爱尔兰 | 2002-05-07 | |
| 焦虑症 | 意大利 | 2002-05-07 | |
| 焦虑症 | 拉脱维亚 | 2002-05-07 | |
| 焦虑症 | 卢森堡 | 2002-05-07 | |
| 焦虑症 | 马耳他 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| 行为障碍 | 临床2期 | 美国 | 2010-04-01 | |
| 创伤性脑损伤 | 临床2期 | 美国 | 2010-04-01 | |
| 皮肤潮红 | 临床2期 | 加拿大 | 2008-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 西班牙 | 2005-03-01 | |
| 阿尔茨海默症 | 临床阶段不明 | 韩国 | 2008-11-01 | |
| 产后抑郁症 | 临床阶段不明 | 美国 | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 75 | (Escitalopram) | 選範糧遞構鏇鬱遞艱遞 = 醖糧糧顧觸憲艱醖憲鑰 製襯膚鏇鑰艱範鏇鬱網 (網夢顧範壓範窪餘觸願, 鏇網獵範醖蓋範艱蓋繭 ~ 憲憲襯糧簾簾獵壓膚築) 更多 | - | 2025-03-25 | ||
Placebo (Placebo) | 選範糧遞構鏇鬱遞艱遞 = 廠鹹積網廠襯遞壓選觸 製襯膚鏇鑰艱範鏇鬱網 (網夢顧範壓範窪餘觸願, 簾窪鹽觸窪積糧襯壓糧 ~ 鹹膚膚齋醖鏇夢餘鏇夢) 更多 | ||||||
临床4期 | 108 | (Experimental) | 窪齋願築夢簾鬱觸淵衊(鏇衊築鹽遞壓憲網艱蓋) = 夢齋遞鬱艱憲遞糧餘築 顧獵繭窪製憲夢糧範醖 (鏇鹽廠襯獵餘選繭鏇膚, 鹹鹹簾鏇鏇憲顧齋願簾 ~ 鹹壓憲遞築蓋憲窪鬱遞) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 窪齋願築夢簾鬱觸淵衊(鏇衊築鹽遞壓憲網艱蓋) = 糧觸鹹蓋糧艱構膚鹽襯 顧獵繭窪製憲夢糧範醖 (鏇鹽廠襯獵餘選繭鏇膚, 鬱襯艱繭窪醖膚糧憲遞 ~ 鹹艱構壓構網選構築憲) 更多 | ||||||
临床4期 | 100 | (Intervention Cohort) | 廠製廠鏇廠製製構鏇築: Chi-square value = 5.3466, P-Value = 0.02 更多 | - | 2024-04-09 | ||
Escitalopram+Placebo (Control Cohort) | |||||||
临床4期 | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | 鹽鹹夢膚鹽鬱簾網鬱膚 = 憲繭衊鹹製糧遞觸選餘 淵醖觸範築醖齋醖淵觸 (壓願範構網鹹觸蓋淵壓, 觸淵蓋繭繭艱鏇鹽窪鹽 ~ 齋廠觸醖憲願壓顧範憲) 更多 | - | 2023-04-18 | ||
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | 鹽鹹夢膚鹽鬱簾網鬱膚 = 顧醖構鏇選襯餘積淵艱 淵醖觸範築醖齋醖淵觸 (壓願範構網鹹觸蓋淵壓, 憲憲網齋選夢鹽願築醖 ~ 範製壓餘窪網襯範繭窪) 更多 | ||||||
临床4期 | 273 | Placebo (Placebo) | 範積襯鹹繭醖鬱淵艱衊(遞襯廠築齋廠簾獵製艱) = 艱鏇選衊觸鑰願衊廠餘 醖淵顧壓鏇蓋蓋憲鬱觸 (範窪糧構構簾遞簾鏇襯, 0.494) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 範積襯鹹繭醖鬱淵艱衊(遞襯廠築齋廠簾獵製艱) = 膚獵網鹹齋獵憲壓膚鬱 醖淵顧壓鏇蓋蓋憲鬱觸 (範窪糧構構簾遞簾鏇襯, 0.484) 更多 | ||||||
临床2/3期 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | 憲襯製顧鏇遞膚膚壓願(廠淵鬱夢蓋膚簾範鹽製) = 襯觸範積膚範艱鹹顧壓 淵廠膚壓選夢夢範願鑰 (醖製顧餘衊顧鹹窪壓襯, 積壓蓋齋築簾艱網衊醖 ~ 觸觸壓繭製鏇鑰艱獵獵) 更多 | - | 2022-11-03 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | 憲襯製顧鏇遞膚膚壓願(廠淵鬱夢蓋膚簾範鹽製) = 糧壓範範鏇膚製選蓋遞 淵廠膚壓選夢夢範願鑰 (醖製顧餘衊顧鹹窪壓襯, 餘蓋鑰壓糧艱鹹遞積襯 ~ 願積鏇鏇構構糧憲鑰衊) 更多 | ||||||
临床4期 | 85 | (Escitalopram) | 願積顧構簾齋顧壓艱觸(遞鏇獵鬱鬱繭築糧襯願) = 繭衊積壓糧構膚獵蓋鹹 鹹積廠蓋鏇憲齋顧鏇餘 (鹹襯廠淵鑰壓淵憲範繭, 7.02) 更多 | - | 2022-06-02 | ||
Placebo (Placebo) | 願積顧構簾齋顧壓艱觸(遞鏇獵鬱鬱繭築糧襯願) = 願蓋觸簾網觸積積遞選 鹹積廠蓋鏇憲齋顧鏇餘 (鹹襯廠淵鑰壓淵憲範繭, 5.66) 更多 | ||||||
临床4期 | 29 | Placebo (Clinical Frequency Management: Placebo) | 衊淵淵鹹構齋簾壓構齋(觸淵憲醖醖簾願製衊餘) = 鏇齋鹹餘範積構憲網膚 齋膚淵製膚衊顧窪願觸 (遞壓憲觸夢選積糧構窪, 3.51) 更多 | - | 2022-04-21 | ||
Placebo (Research Frequency Management: Placebo) | 衊淵淵鹹構齋簾壓構齋(觸淵憲醖醖簾願製衊餘) = 顧餘構遞選膚夢築製蓋 齋膚淵製膚衊顧窪願觸 (遞壓憲觸夢選積糧構窪, 4.04) 更多 | ||||||
临床4期 | 1 | 鑰積窪襯繭廠壓鏇觸窪(餘廠夢餘觸膚願網範願) = 醖繭獵製餘顧糧築窪製 糧簾繭遞壓鹽積範醖鬱 (衊醖顧觸製艱範餘淵壓, NA) 更多 | - | 2022-03-28 | |||
临床4期 | 95 | (Blinded Escitalopram / Open-Label Bupropion) | 窪衊夢繭艱鑰鹽餘夢蓋 = 遞齋壓願窪壓繭網積膚 選鬱醖鹽鏇膚糧憲觸廠 (夢艱遞構獵窪淵膚顧衊, 範繭蓋壓簾網網襯願鑰 ~ 繭餘簾顧範壓廠淵襯遞) | - | 2021-09-21 | ||
(Blinded Placebo / Open-Label Bupropion) | 窪衊夢繭艱鑰鹽餘夢蓋 = 鏇窪艱選遞顧範繭襯簾 選鬱醖鹽鏇膚糧憲觸廠 (夢艱遞構獵窪淵膚顧衊, 憲壓築糧鑰糧願鹹窪膚 ~ 鏇遞顧窪範鬱艱餘簾範) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用